|
|
||||||||
State University of New York at Buffalo, Buffalo, New York
Correspondence: For reprints contact: Hank F. Kung, Dept. of Nuclear Medicine, VA Medical Center, 3495 Bailey Ave., Buffalo, NY 14215.
ABSTRACT
This paper proposes a new mechanism for radiopharmaceutical uptake, which may be applicable to a variety of clinical studies. Many tissues and organs have low intracellular pH, either normally or as a result of various metabolic disturbances. We have developed a series of compounds that are neutral and lipid-soluble at blood pH. These molecules can diffuse freely into cells. In those regions where intracellular pH is low, they pick up a hydrogen ion and become charged. In this form they are no longer lipid-soluble and are trapped because they cannot diffuse out of the cell. Studies of the brain uptake of two compounds of this type, Se-75 labeled di-ß-(morpholinoethyl)-selenide (MOSE) and di-ß-(piperidinoethyl)-selenide (PIPSE), demonstrate the application of the principle.
This article has been cited by other articles:
![]() |
D. C. Costa Single photon emission tomography (SPET) with 99Tc m-hexamethylpropyleneamineoxime (HMPAO) in research and clinical practice - a useful tool Vascular Medicine, September 1, 1990; 1(2): 179 - 201. [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |